ChartMill assigns a Buy % Consensus number of 78% to VYNE. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-07-30 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-04-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-18 | BTIG | Initiate | Buy |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-12 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-05-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-19 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-30 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-14 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-08-10 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-07 | HC Wainwright & Co. | Maintains | Buy |
10 analysts have analysed VYNE and the average price target is 3.32 USD. This implies a price increase of 491.96% is expected in the next year compared to the current price of 0.56.
The consensus rating for VYNE THERAPEUTICS INC (VYNE) is 78 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering VYNE THERAPEUTICS INC (VYNE) is 10.